A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

645

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis
Inflammatory Bowel Diseases
Colitis
Colitis, Ulcerative

Interventions

DRUG: SPY001
DRUG: SPY002
DRUG: SPY003
OTHER: Placebo

Sponsor

Spyre Therapeutics, Inc.